Nov 13th 2012 - Edison Investment Research today published a report on Clavis Pharma entitled "The Ride Of The Valkyries". In summary, the report says:
The pivotal LEAP Phase II/III study in metastatic pancreatic cancer delivered an unambiguously negative result, failing to show a survival advantage for CP-4126 vs gemcitabine or indeed provide any evidence in support the hENT1 hypothesis. All development work on CP-4126 has been suspended and the termination of the Clovis collaboration now seems inevitable. Clavis’ investment case is thus now entirely focused on the outcome, due in late Q113, of the CLAVELA Phase III study of elacytarabine in acute myeloid leukaemia. The CP-4126 failure triggered an 87% fall in Clavis’ share price, leaving the shares trading at little above their cash value (NOK7.80/share).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »